PDCD1 and colorectal carcinoma: Although immunotherapy has produced durable responses in MSI-H CRC, with recent FDA approval of pembrolizumab in the first-line setting of metastatic CRC (93), MSS CRC has long been considered resistant to PD-1/PD-L1 blockade.